Emovi is accelerating its growth through a 15M$ Series C investment led by TVM Capital Life Science
MONTREAL, March 4, 2019 /CNW Telbec/ – Emovi announced today its partnership with TVM Capital Life Science and co-investors StandUp Ventures and Desjardins Capital to support its global commercial activities. This 15M$ Series C investment is combined with other capital for a total of 20M$.
With this capital infusion, Emovi will be able to support its goal of driving clinical adoption for its core product, KneeKG. Emovi is proud to promote the commercial expansion by offering its KneeKG product to a larger number of clinics and hospitals across North America.
“I am proud to partner with world-class venture capital funds to ensure that Emovi will become a major player in the global orthopaedic and sports medicine field. These investments enable us to support clinical adoption of our product in Canada, the United States and Europe” – Michelle Laflamme, President and CEO.
“Emovi commercializes an innovative medical device targeting a very important need: the need to better understand and treat causes of knee pain with objective data. This is a common need world-wide. Our investment will position Emovi as a world leader while concurrently keeping its corporate roots in the province of Quebec. Emovi will benefit from TVM Capital Life Science’s European and North-American network to facilitate its market access abroad.” – Dr. Luc Marengere, Managing Partner, TVM Capital Life Science.
To better meet demand, Emovi plans to continue to increase its number of employees as well as its production capabilities in the months to come. Emphasis will be placed on additional product adoption by health professionals in order to better support market expansion.
About Emovi
Emovi (Emovi.ca), headquartered in Montreal, Quebec, Canada, is a company offering medical solutions for joints assessments. In partnership with the Quebec university research community, including the CRCHUM and École de technologie supérieure (ÉTS), Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi hopes to broaden access to this technology and improve the quality of life for people struggling with diseases such as knee osteoarthritis, ligament or meniscus tears, patellofemoral
